This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
by Zacks Equity Research
Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
Incyte (INCY) Initiates Essential Thrombocythemia Trial
by Zacks Equity Research
Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
by Zacks Equity Research
Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.
What's in the Offing for Intercept (ICPT) in Q3 Earnings?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.
Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite
by Zacks Equity Research
Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite
What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
by Zacks Equity Research
Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.
Will Radius Health (RDUS) Disappoint This Earnings Season?
by Zacks Equity Research
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Get Rid of These 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are vulnerable to outside shocks and are burdened with high amounts of debts. Also, the price of toxic stocks is inflated.
Why Incyte (INCY) Might Surprise This Earnings Season
by Zacks Equity Research
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
5 Toxic Stocks to Abandon or Sell Short for Gains
by Zacks Equity Research
Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
by Zacks Equity Research
Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite
5 Toxic Stocks to Discard or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
Top Research Reports for Bank of America, Pepsi & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), American Express (AXP), and Pepsi (PEP).
Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected
by Zacks Equity Research
Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.
Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong
by Zacks Equity Research
Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
by Arpita Dutt
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?